TABLE 3.

Best Overall Response to Platinum-based Therapies According to the Scheme, Tumor Differentiation, and for Well-Differentiated PanNET, Grade

Pancreatic Neuroendocrine Neoplasms (n = 101)
	Platinum/Etoposide			Platinum/Irinotecan			Platinum/Gemcitabine			Oxaliplatin/5-FU			Platinum
Characteristic	PR (n = 16)	SD (n = 20)	POD (n = 21)	PR (n = 3)	SD (n = 4)	POD (n = 2)	PR (n = 6)	SD (n = 8)	POD (n = 3)	PR (n = 5)	SD (n = 9)	POD (n = 1)	PR (n = 1)	SD (n = 1)	POD (n = 1)
Well-differentiated (PanNET),	2/17 (12)	8/17 (47)	7/17 (41)	0/5 (0)	3/5 (60)	2/5 (40)	4/13 (31)	6/13 (46)	3/13 (23)	4/13 (31)	9/13 (69)	0/13 (0/0)	0/2 (0)	1/2 (50)	1/2 (50)
Grade 1	0/2 (0)	1/2 (50)	1/2 (50)	0/0 (0)	0/0 (0)	0/0 (0)	1/2 (50)	1/2 (50)	0/2 (0)	1/2 (50)	1/2 (50)	0/2 (0)	0 /0 (0)	0/0 (0)	0/0 (0)
Grade 2	1/6 (17)	4/6 (67)	1 /6 (17)	0/2 (0)	1/2 (50)	1/2 (50)	1/6 (17)	2/6 (33)	3/6 (50)	0/4 (0)	4/4 (83)	0/4 (17)	0/1 (0)	0/1 (0)	1/1 (100)
Grade 3	1/9 (11)	3/9 (33)	5/9 (56)	0/3 (0)	2/3 (67)	1/3 (33)	2/4 (50)	2/4 (50)	0/4 (0)	3/7 (38)	4/7 (62)	0/7 (0)	0/1 (0)	1/1 (100)	0/1 (0)
Poorly differentiated (PanNEC)	7/22 (32)	8/22 (36)	7/22 (32)	3/4 (75)	1/4 (25)	0/4 (0)	1/2 (50)	1/2 (50)	0/2 (0)	0/0 (0)	0/0 (0)	0/0 (0)	1/1 (100)	0/1 (0)	0/1 (0)
Unknown differentiation	7/18 (39)	4/18 (22)	7/18 (39)	0/0 (0)	0/0 (0)	0/0 (0)	1/2 (50)	1/2 (50)	0/2 (0)	1/2 (50)	0/2 (0)	1/2 (50)	0/0 (0)	0/0 (0)	0/0 (0)

Proportions and perentages are expressed in row.

PanNEN indicates pancreatic neuroendocrine neoplasm; PanNET, pancreatic neuroendocrine tumor; PanNEC, pancreatic neuroendocrine cancer; PR, partial response; SD, stability of disease; POD, progression of disease.